J&J Divests OTC Anti-Dandruff Product To Separate Buyers Across 3 Regions
This article was originally published in The Pink Sheet & The Rose Sheet
J&J agrees to sell marketing rights to its OTC 1% ketoconazole dandruff treatment product to Kramer Labs in the US and Latin America, to German firm Stada in the EMEA and to UK firm Alliance Pharma for the Asia-Pacific market as it continues to spin off non-core brands and focus on its core $1bn brands.
You may also be interested in...
Only US OTC Ketoconazole Dandruff Shampoo Approved For 'Professional Sample' Marketing
With Nizoral A-D sample packages approved for distribution, Arcadia has opportunity to expand sales by providing samples which dermatologists and other doctors can offer and recommend to patients.
Alliance Pharma Eyes OTC Acquisitions Following Strong 2021
UK-based Alliance Pharma saw sales rise double-digits in 2021, with acquisitions bolstering the performance of its established brands. Going into 2022, the company says it is in a strong position to pursue M&A in the consumer health space.
Sanofi Continues Consumer Health Trim, Sells Kaopectate US Rights To Arcadia
Sanofi sells US rights to anti-diarrhea Kaopectate brand to Arcadia Consumer Healthcare, which plans to invest in marketing and innovation behind the brand. Arcadia also markets the Nizoral dandruff shampoo and Fungi-Nail consumer health brands.